U.S. Healthcare Contract Development And Manufacturing Organization Market (2025 - 2033)

U.S. Healthcare Contract Development And Manufacturing Organization Market Summary

The U.S. healthcare contract development and manufacturing organization market size was estimated at USD 65.3 billion in 2024 and is projected to reach USD 144.2 billion by 2033, growing at a CAGR of 9.41% from 2025 to 2033. The U.S. healthcare CDMO market is expanding rapidly, driven by rising demand for biologics, biosimilars, and advanced therapies, including cell and gene therapies. Besides, pharmaceutical companies are increasingly focused on R&D in oncology, rare diseases, and immunology, creating the need for highly specialized manufacturing expertise.

CDMOs provide critical infrastructure, scalability, and technical capabilities that many firms lack internally. Growth is further reinforced by strong pipeline activity, patent expirations of biologics, and the acceleration of personalized medicine. This has led CDMOs to become essential partners in enabling faster development timelines, cost efficiency, and compliant production of complex therapies. Pharmaceutical and biotech companies are partnering with CDMOs to reduce operational costs and accelerate product development. Besides, among pharmaceutical companies, establishing in-house facilities requires substantial capital investment, workforce training, and regulatory compliance, which may slow innovation, which has further led to the rise of CDMO services.

In addition, CDMOs offer pharmaceutical and medical device companies’ immediate access to advanced technologies, large-scale facilities, and flexible production models. This partnership supports minimizing the financial risks and allows pharma companies to focus on core R&D while leveraging CDMOs for clinical and commercial manufacturing. In a highly competitive market where speed is critical, CDMOs offer an agile and cost-efficient pathway to bring drugs to market faster, ensuring competitive advantage and profitability.

The U.S. healthcare industry operates under stringent FDA and global regulatory frameworks, requiring strict adherence to GMP standards, validation, and documentation. Besides, navigating these compliance requirements can be highly resource-intensive for pharma companies. CDMOs, however, possess deep regulatory expertise, established quality systems, and experience managing global submissions, reducing the risk of delays and non-compliance. Their ability to consistently meet evolving regulatory standards enhances trust and reliability. In addition, CDMOs are investing in digitalization, automation, and data-driven compliance systems to strengthen oversight. This regulatory know-how makes CDMOs indispensable strategic partners, enabling pharma companies to focus on innovation while ensuring product quality and patient safety.

Opportunity Analysis

The U.S. healthcare CDMO market is experiencing strong growth, driven by evolving therapeutic pipelines, technological advances, and shifting industry dynamics. Expansion in biologics and advanced therapies, particularly cell, gene, and mRNA-based treatments, is creating substantial opportunities for CDMOs to invest in specialized infrastructure, high-containment facilities, and high-value services. At the same time, the rising number of small and emerging biotech companies without in-house manufacturing capacity fuels reliance on outsourcing, providing CDMOs with an expanding client base. Besides, increasing demand for flexible manufacturing, including modular, multi-product, and continuous production systems, underscores the need for scalable, adaptable solutions that CDMOs are well-positioned to deliver. Moreover, digital transformation is reshaping the industry with CDMOs integrating AI, automation, and advanced data analytics into development & manufacturing processes to enhance efficiency, ensure quality, and enable innovative service models. In addition, global supply chain realignments are driving U.S. pharmaceutical and biotech companies to reduce reliance on overseas facilities, creating opportunities for domestic CDMOs to strengthen capacity and expand operations. Thus, these trends position CDMOs as critical partners to accelerate innovation, ensure regulatory compliance, and meet the growing demand for complex, next-generation healthcare solutions in the U.S. market.

Impact of U.S. Tariffs on the U.S. Healthcare Contract Development and Manufacturing Organization Market

U.S. tariffs have impacted the healthcare CDMO market by reshaping cost structures, supply chains, and strategic decisions. Tariffs on raw materials, APIs, excipients, & specialized equipment imported from overseas increase production costs and pressure contract manufacturers. These added expenses often translate into higher service pricing or margin compression for CDMOs. Moreover, tariffs have led pharmaceutical and biotechnology companies to shift away from global supply dependencies, creating opportunities for domestic CDMOs to expand capacity and capture a larger share of outsourced projects. However, supply chain disruptions, longer lead times, and higher input costs present operational challenges. Overall, tariffs are accelerating the realignment of CDMO operations in the U.S., strengthening domestic manufacturing but raising cost competitiveness concerns.

Technological Advancements

Technological advancements are transforming the market enabling faster, more efficient, and higher-quality drug development and manufacturing. Continuous manufacturing is gaining traction as it improves scalability, reduces production timelines, and ensures consistent product quality. Besides, advanced analytical techniques support precise characterization, quality control, and regulatory compliance, particularly for complex biologics and advanced therapies. Artificial intelligence and data analytics are increasingly integrated to optimize process design, predict outcomes, and enhance decision-making across development and manufacturing stages. Besides, single-use bioprocessing systems provide flexibility, lower contamination risks, and cost efficiencies, making them especially valuable for multi-product facilities and smaller batch production.

In addition, automation and robotics are streamlining operations by minimizing human error, increasing throughput, and ensuring safety in handling high-potency compounds. Collectively, these innovations position CDMOs as indispensable partners in advancing next-generation therapies while meeting stringent regulatory and market demands.

Pricing Model Analysis

Pricing models in the U.S. market are evolving to effectively balance the diverse needs of clients with the complexities of services offered. Milestone-based pricing associates payments with specific project achievements, such as formulation completion, clinical supply provision, or regulatory submission, fueling flexibility and shared risk for multi-phase projects. Besides, value-based pricing highlights outcomes linking fees to measurable benefits such as expedited timelines, enhanced yields, or increased approval success rates, making it particularly suitable for advanced therapies and high-value biologics. In addition, the fixed-fee model ensures predictability by a set cost for defined services further providing transparency and budget particularly for routine manufacturing or testing activities.

Moreover, the subscription model facilitates recurring payments for ongoing access to CDMO expertise and infrastructure, ensuring clients receive long-term support and priority access, while providing CDMOs with a stable revenue stream. Thus, these pricing models drive the industry's shift toward strategic partnerships, aligning cost structures with innovation, risk management, and operational efficiency in drug development and manufacturing.

Market Concentration & Characteristics

The healthcare contract development and manufacturing organization market growth stage is moderate, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.

Innovation is central to U.S. CDMOs, with strong adoption of continuous manufacturing, single-use bioprocessing, AI-driven analytics, and advanced biologics capabilities. Companies invest heavily in R&D partnerships and digital platforms to enhance efficiency, scalability, and compliance. This innovative approach enables CDMOs to address growing demand for complex biologics, person alized therapies, and high-value manufacturing services.

M&A activity in the U.S. CDMO market remains high, driven by the need to expand service portfolios, increase scale, and strengthen geographic presence. Strategic acquisitions allow CDMOs to enter biologics, cell and gene therapy, and sterile injectables segments. Consolidation also improves bargaining power with pharmaceutical clients, creating integrated players capable of providing end-to-end solutions.

Strict FDA and global regulatory frameworks heavily influence U.S. CDMOs. Compliance with GMP standards, data integrity, and quality assurance is vital for securing contracts. While regulations increase operational costs, they also serve as entry barriers, giving established CDMOs a competitive advantage. In addition, regulatory expertise strengthens client trust and supports market growth in advanced therapeutics manufacturing.

U.S. CDMOs are expanding services beyond traditional drug manufacturing into drug discovery support, formulation development, clinical trial material supply, and commercialization assistance. In June 2024, Bionova Scientific, U.S. biologics CDMO of Asahi Kasei Group, will establish a Texas facility and launch a plasmid DNA business to support cell and gene therapies, mRNA vaccines, and antibody drugs. This broadening scope positions CDMOs as strategic partners, enabling pharmaceutical clients to streamline development cycles and reduce time-to-market.

Regional expansion is driven by investments in domestic facilities to mitigate supply chain risks and reliance on imports. Many also expand globally, targeting Europe and Asia-Pacific markets to capture outsourcing demand. In November 2024, Ascend Advanced Therapies partnered with EW Healthcare Partners, integrating ABL’s Rockville facility to expand U.S. GMP capacity, viral vector capabilities, and fill/finish services, creating a comprehensive gene-to-commercial CDMO offering.

Type Insights

On the basis of type segment, in 2024, the small molecule segment held the largest market share in the market, accounting for a revenue share of 41.09%. The segment is gaining momentum due toits established role as a small molecule in pharmaceutical development and widespread therapeutic use. Despite the growing focus on biology, small molecules continue to witness the growth of emerging drug pipelines for oncology, cardiovascular, and infectious diseases. In addition, CDMOs provide API development, formulation, and commercial-scale manufacturing capabilities supported by cost efficiency and regulatory expertise. Generic drug production further strengthens demand as patent expirations fuel outsourcing. Moreover, advancements in HPAPIs and complex formulations create new opportunities. This demand and versatility make small molecules the cornerstone of CDMO growth in the U.S. market.

The large molecule segment is expected to grow significantly during the forecast period. The segment is fueled by rising demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies. Besides, biopharmaceutical companies increasingly outsource CDMOs for complex process development, scale-up, and GMP manufacturing expertise. The surge in monoclonal antibodies, recombinant proteins, and mRNA-based therapeutics further accelerates segment growth. CDMOs invest heavily in bioreactors, single-use systems, and advanced analytical platforms to meet demand. Personalized medicine, rare disease treatments, and ongoing R&D pipelines drive expansion, making large molecules the leading growth engine for U.S. CDMO market evolution.

Product Insights

On the basis of product, the pharmaceutical segment dominated the market with the largest revenue share in 2024. Extensive outsourcing requirements across drug discovery, development, and commercial manufacturing drive the segment growth. With increasing demand for cost efficiency, scalability, and regulatory compliance, pharma companies mostly rely on CDMOs to optimize operations and focus on core R&D. The rise of generics, complex formulations, and high-potency APIs further boosts outsourcing activity. In addition, CDMOs provide flexible solutions for lifecycle management, clinical trial materials, and global supply chain support. Thus, with the expansion of pharmaceutical pipelines in oncology, cardiovascular, and chronic diseases, CDMOs are anticipated to establish themselves as critical partners, further contributing to market growth.

The medical devices segment is expected to grow significantly during the forecast period. The segment's growth is propelled by rising demand for outsourcing design, development, and manufacturing services. Increasing regulatory complexity and the need for rapid innovation drive device companies to partner with CDMOs for specialized expertise and cost-effective solutions. Growth is supported by advancements in minimally invasive devices, diagnostics, and combination products integrating drugs and devices. CDMOs are expanding capabilities in prototyping, precision engineering, and compliance with FDA standards to meet evolving needs. With an aging population, rising chronic diseases, and technological innovations, medical devices represent a key growth engine in the market

Service Insights

On the basis of service, the contract manufacturing segment accounted for the largest share in 2024 during the forecast period. Contract manufacturing is expected to witness new growth opportunities in the U.S. market owing to its critical role in supporting pharmaceutical, biotech, and medical device companies. It covers various services, including active pharmaceutical ingredient (API) production, formulation development, fill-finish operations, and packaging. Besides, the companies increasingly rely on CDMOs to meet growing demand while avoiding heavy capital expenditure on in-house facilities and specialized technologies. This outsourcing model ensures scalability, operational efficiency, and compliance with stringent FDA and global regulatory standards.

The segment's growth is further fueled by the rising complexity of drug pipelines particularly biologics, biosimilars, and high-potency APIs (HPAPIs) which require advanced technical expertise and dedicated infrastructure. CDMOs also invest in innovative technologies such as continuous manufacturing, single-use systems, and digital quality management to enhance flexibility and speed. In addition, the expansion of generics and specialty drugs drives steady demand for cost-effective large-scale production. Growing needs for lifecycle management, global supply chain resilience, and rapid time-to-market reinforce contract manufacturing's requirement. As pharma and biotech companies increasingly focus on R&D and commercialization, CDMOs are positioned as indispensable partners, making contract manufacturing the cornerstone of current and future U.S. CDMO market expansion.

The contract development segment is expected to grow significantly during the forecast period. This service plays a crucial role as it provides essential support to pharmaceutical & biotechnology companies in various early-stage activities such as formulation, analytical testing, process optimization, and preparing materials for clinical trials. The increasing demand for biologics, biosimilars, and complex small molecules has increased reliance on CDMOs for their specialized expertise and infrastructure. In addition, the complexities of regulatory compliance and ongoing cost pressures motivate firms to outsource these tasks, ultimately fostering faster and more efficient development pathways. By delivering integrated solutions, CDMOs enhance their clients' pipelines and facilitate the smooth transition from discovery to commercialization.

Workflow Insights

On the basis of workflow, the commercial segment dominated the market with the largest revenue share in 2024. The segment growth is driven by increasing demand for large-scale drug manufacturing and market-ready supply. Pharmaceutical and biotech companies rely on CDMOs for cost-efficient production, fill-finish, packaging, and distribution of approved therapies, including biologics, small molecules, and specialty drugs. Some other factors contributing to segment growth are expanding pipelines, generics, and complex therapies requiring advanced manufacturing capabilities. CDMOs’ expertise in GMP compliance, scalability, and quality assurance enables faster time-to-market and reliable supply. Thus, rising outsourcing trends and the commercialization of innovative therapies are expected to drive the market growth.

On the other hand, the clinical segment is projected to grow at a significant CAGR during the forecast period. The segment growth is driven by increasing demand for outsourced development and manufacturing of investigational drugs for clinical trials. Pharmaceutical and biotech companies rely on CDMOs for small- and mid-scale production, formulation, and packaging of clinical trial materials, ensuring compliance with GMP and regulatory standards. Expanding early-phase pipelines, personalized medicine, and complex biologics requiring specialized handling further fueled the segment growth. In addition, CDMOs offer flexibility, scalability, and rapid turnaround times, enabling faster study initiation and patient recruitment. This rising reliance on outsourced clinical manufacturing is anticipated to drive the U.S. CDMO market growth.

Therapeutic Area Insights

On the basis of therapeutic area, the oncology segment accounted for the largest share in 2024 during the forecast period. In the U.S., the rising prevalence of cancer is creating a critical demand for cancer therapeutics, creating an increasing requirement for drugs with small molecules, biologics, and advanced modalities such as cell and gene therapies. The growing cancer burden and the expansion of oncology-focused R&D pipelines drive pharmaceutical and biotechnology companies to outsource development, manufacturing, and commercialization activities to CDMOs. Since oncology drugs are often complex and highly potent and require specialized handling, process development, and GMP-compliant manufacturing, CDMOs have become indispensable partners in advancing these therapies to market.

The growth is further accelerated by the rising requirement for personalized medicine, immuno-oncology, and targeted therapies, which demand highly precise and scalable production capabilities. CDMOs provide advanced analytical tools, single-use bioreactors, fill-finish solutions, and regulatory expertise to ensure quality, safety, and speed to market. In addition, outsourcing enables pharmaceutical companies to optimize costs, manage risks, and focus on R&D innovation while CDMOs handle manufacturing complexities.

The autoimmune diseases segment is expected to grow significantly during the forecast period. In the U.S., the rising incidence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and lupus, is fueling demand for innovative therapeutics. Drug development in this field increasingly emphasizes biologics, monoclonal antibodies, and advanced therapies that require specialized expertise in formulation, scale-up, and manufacturing. In addition, pharmaceutical & biotech companies are expanding pipelines to address unmet needs, driving reliance on CDMOs for development and GMP-compliant production. With complex manufacturing requirements and stringent regulatory standards, CDMOs are pivotal in delivering safe, effective autoimmune disease therapies.

End Use Insights

On the basis of End Use, the pharmaceutical & biotechnology companies segment accounted for the largest share in 2024 during the forecast period. With pipelines expanding across small molecules, biologics, high-potency APIs, and advanced modalities such as cell and gene therapies, the pharmaceutical companies increasingly rely on CDMOs to meet rising development and manufacturing demands. CDMOs provide critical expertise in formulation, process development, clinical trial material supply, and scalable GMP-compliant production. By outsourcing specialized partners, pharmaceutical & biotechnology companies gain access to advanced technologies, reduce operational risks, and accelerate time-to-market, enabling the efficient delivery of innovative therapies to address complex and unmet medical needs. Such factors are expected to drive the market over the estimated time period.

Some other factors contributing to segment growth are increasing R&D investments, patent expirations of blockbuster drugs, and the rising availability of generics and biosimilars, which are accelerating outsourcing activities. Furthermore, the shift toward personalized medicine, immunotherapies, and next-generation biologics demands advanced process development & analytical expertise that many in-house facilities cannot provide. CDMOs address these needs by offering cutting-edge technologies such as single-use bioprocessing, continuous manufacturing, and digital quality management systems, supporting companies to achieve faster time-to-market while ensuring regulatory compliance and operational efficiency.

The medical device companies segment is expected to grow at the second-highest CAGR during the forecast period. Medical device companies are an essential segment driving demand in the U.S. healthcare CDMO market, as rising product complexity and stringent regulatory standards increase outsourcing needs. From implantable devices and diagnostics to drug-device combination products, development requires specialized expertise in materials science, precision engineering, sterilization, and packaging. In addition, CDMOs support medical device companies with design optimization, prototyping, clinical trial material supply, and large-scale GMP-compliant manufacturing. By leveraging CDMOs’ advanced technologies and regulatory knowledge, medical device companies accelerate product development, reduce costs, and ensure timely commercialization in a competitive market.

Key Healthcare Contract Development And Manufacturing Company Insights

The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in October 2024, Thermo Fisher Scientific launched Accelerator Drug Development at CPHI Milan 2024, offering end-to-end CDMO and CRO services for small molecules, biologics, and cell and gene therapies. The platform provides customizable manufacturing, clinical research, and supply chain solutions, supporting pharmaceutical and biotech companies across all stages of drug development with speed, quality, and efficiency.

Recent Developments

• In November 2024, Ascend Advanced Therapies partnered with EW Healthcare Partners, integrating ABL’s Rockville facility to expand U.S. GMP manufacturing, viral vector, and fill-finish capabilities, strengthening its gene-to-GMP CDMO services.

• In October 2024, Thermo Fisher launched Accelerator Drug Development at CPHI Milan 2024, offering end-to-end CDMO and CRO services for small molecules, biologics, and cell/gene therapies, enhancing speed, quality, and regulatory compliance.

• In June 2024, Bionova Scientific, U.S. biologics CDMO of Asahi Kasei, will open a Texas facility for plasmid DNA services, supporting cell/gene therapies, mRNA vaccines, and antibody drugs, expanding its advanced therapeutic capabilities.

U.S. Healthcare Contract Development and Manufacturing Organization Market